MX2022012541A - Inmunoconjugados. - Google Patents

Inmunoconjugados.

Info

Publication number
MX2022012541A
MX2022012541A MX2022012541A MX2022012541A MX2022012541A MX 2022012541 A MX2022012541 A MX 2022012541A MX 2022012541 A MX2022012541 A MX 2022012541A MX 2022012541 A MX2022012541 A MX 2022012541A MX 2022012541 A MX2022012541 A MX 2022012541A
Authority
MX
Mexico
Prior art keywords
immunoconjugates
polypeptides
mutant interleukin
polynucleotide molecules
relates
Prior art date
Application number
MX2022012541A
Other languages
English (en)
Inventor
Pablo Umaña
Anne Freimoser-Grundschober
Christian Klein
Ekkehard Moessner
Deak Laura Codarri
Laura Lauener
Cindy Schulenburg
Eleni Maria Varypataki
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022012541A publication Critical patent/MX2022012541A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere en general a polipéptidos de interleucina-7 mutante, inmunoconjugados, particularmente inmunoconjugados que comprenden un polipéptido de interleucina-7 mutante y un anticuerpo que se fija a PD-1. Además, la invención se refiere a moléculas de polinucleótidos que codifican los polipéptidos de interleucina-7 mutante o los inmunoconjugados, y vectores y células huésped que comprenden dichas moléculas de polinucleótidos. La invención se refiere además a métodos para producir los polipéptidos de interleucina-7 mutante, inmunoconjugados, composiciones farmacéuticas que los comprenden, y usos de estos.
MX2022012541A 2020-04-15 2021-04-13 Inmunoconjugados. MX2022012541A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20169510 2020-04-15
PCT/EP2021/059473 WO2021209402A2 (en) 2020-04-15 2021-04-13 Immunoconjugates

Publications (1)

Publication Number Publication Date
MX2022012541A true MX2022012541A (es) 2022-11-07

Family

ID=70289616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012541A MX2022012541A (es) 2020-04-15 2021-04-13 Inmunoconjugados.

Country Status (17)

Country Link
US (1) US20230192795A1 (es)
EP (1) EP4135848A2 (es)
JP (1) JP2023521238A (es)
KR (1) KR20230004494A (es)
CN (1) CN115485028A (es)
AR (1) AR121856A1 (es)
AU (1) AU2021256936A1 (es)
BR (1) BR112022020629A2 (es)
CA (1) CA3168460A1 (es)
CL (1) CL2022002751A1 (es)
CO (1) CO2022014884A2 (es)
CR (1) CR20220512A (es)
IL (1) IL294451A (es)
MX (1) MX2022012541A (es)
PE (1) PE20230111A1 (es)
TW (1) TW202200609A (es)
WO (1) WO2021209402A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240041379A (ko) * 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Il-2에 접합된 체크포인트 억제제 및 이의 용도
WO2023062048A1 (en) * 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag Alternative pd1-il7v immunoconjugates for the treatment of cancer
AU2022362681A1 (en) * 2021-10-14 2024-04-04 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001025454A2 (en) 1999-10-04 2001-04-12 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ATE378403T1 (de) 2000-11-30 2007-11-15 Medarex Inc Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
JP4753578B2 (ja) 2002-06-03 2011-08-24 ジェネンテック， インコーポレイテッド 合成抗体ファージライブラリー
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP2402374A1 (en) 2005-02-07 2012-01-04 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
CA2820956C (en) * 2010-12-10 2016-05-03 University Of Central Florida Research Foundation, Inc. Methods and compositions comprising il-7 receptor ligands
DK3489255T3 (da) 2011-02-10 2021-08-23 Roche Glycart Ag Muterede interleukin-2-polypeptider
EP3590965A1 (en) 2011-03-29 2020-01-08 Roche Glycart AG Antibody fc variants
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PT2794905T (pt) 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
CA3159061A1 (en) 2012-02-15 2013-08-22 F. Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
NZ630551A (en) 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules
RS62450B1 (sr) 2015-10-02 2021-11-30 Hoffmann La Roche Anti-pd1 antitela i postupci primene
WO2017055404A1 (en) * 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
MX2019006897A (es) * 2016-12-13 2019-08-22 Astellas Pharma Inc Anticuerpo anti cd73 humana.
WO2018156649A1 (en) * 2017-02-22 2018-08-30 Flagship Pioneering, Inc. Compositions of t cell modulator (tcm) molecules and uses thereof
JP7102670B2 (ja) * 2018-01-25 2022-07-20 アイ－エムエービー バイオファーマ ユーエス リミテッド 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
JP2022514702A (ja) * 2018-12-21 2022-02-14 オーエスイー・イミュノセラピューティクス 二機能性抗ｐｄ－１／ｉｌ－７分子
BR112021012027A2 (pt) * 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula bifuncional direcionada contra pd-1 humano
JP2022532249A (ja) * 2019-05-16 2022-07-13 アーチ オンコロジー，インコーポレイテッド インターロイキンタンパク質の類似体と組み合わせて癌を処置するための治療用組成物及び方法

Also Published As

Publication number Publication date
KR20230004494A (ko) 2023-01-06
CN115485028A (zh) 2022-12-16
WO2021209402A2 (en) 2021-10-21
CR20220512A (es) 2022-11-07
IL294451A (en) 2022-09-01
US20230192795A1 (en) 2023-06-22
CA3168460A1 (en) 2021-10-21
TW202200609A (zh) 2022-01-01
AR121856A1 (es) 2022-07-20
BR112022020629A2 (pt) 2022-11-29
CO2022014884A2 (es) 2022-11-08
WO2021209402A3 (en) 2021-12-02
CL2022002751A1 (es) 2023-05-19
JP2023521238A (ja) 2023-05-23
AU2021256936A1 (en) 2022-07-21
PE20230111A1 (es) 2023-01-27
EP4135848A2 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
MX2019011770A (es) Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
CR20220512A (es) Inmunoconjugados
WO2018151868A3 (en) Albumin binding domain fusion proteins
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
MA35803B1 (fr) Polypeptides d'interleukine-2 mutants
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
MX2022005252A (es) Composiciones de escherichia coli y metodos de las mismas.
AU2018253611A1 (en) Engineered pesticidal proteins
FI20225221A1 (fi) Ei-eläinperhjaisia proteiinilähteitä funktionaalisilla ominaisuuksilla
WO2011056954A8 (en) Haemophilus parasuis polypeptides and methods of use
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
MX2021000322A (es) Enzimas de variante fosfopentomutasa modificada geneticamente.
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
MX2018013778A (es) Mutante cd200 y sus usos.
MY193355A (en) Anti-vegf protein compositions and methods for producing the same
AR119338A1 (es) Inmunoconjugados que comprenden un polipéptido interleuquina-2 (il-2) mutante y un anticuerpo que se une a cd8
AU2018277310A1 (en) Aggrecan binding immunoglobulins
MX2019014400A (es) Inmunoglobulinas que se unen a adamts.
ZA202104048B (en) Anti-il-17a antibody and use thereof
MX2019014397A (es) Polipeptidos que enlazan adamts5, mmp13 y agrecano.
MX2019014448A (es) Inmunoglobulinas de enlace a mmp13.
CR20230219A (es) Polipéptidos de interleucina-2 mutante dependientes del ph
PH12020500087A1 (en) Immunogenic compositions comprising cea muc1 and tert
MX2022007919A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.